{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:13:09Z","timestamp":1791274389993,"version":"4.1.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.nucmedbio.2007.06.015","type":"journal-article","created":{"date-parts":[[2007,9,5]],"date-time":"2007-09-05T11:26:49Z","timestamp":1188991609000},"page":"809-822","source":"Crossref","is-referenced-by-count":106,"title":["Impact of amyloid imaging on drug development in Alzheimer's disease"],"prefix":"10.1016","volume":"34","author":[{"given":"Chester A.","family":"Mathis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Lopresti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Klunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.nucmedbio.2007.06.015_bib1","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/archneur.60.8.1119","article-title":"Alzheimer disease in the US population: prevalence estimates using the 2000 census","volume":"60","author":"Hebert","year":"2003","journal-title":"Arch Neurol"},{"issue":"4\u20135","key":"10.1016\/j.nucmedbio.2007.06.015_bib2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/BF02189530","article-title":"Cross-national comparisons of the occurrence of Alzheimer's and vascular dementias","volume":"240","author":"Jorm","year":"1991","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.nucmedbio.2007.06.015_bib3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/WNL.41.4.479","article-title":"The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease","volume":"41","author":"Mirra","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.nucmedbio.2007.06.015_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0896-6273(94)90458-8","article-title":"Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43)","volume":"13","author":"Iwatsubo","year":"1994","journal-title":"Neuron"},{"key":"10.1016\/j.nucmedbio.2007.06.015_bib5","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/0166-2236(93)90078-Z","article-title":"Tau protein and the neurofibrillary pathology of Alzheimer's disease","volume":"16","author":"Goedert","year":"1993","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.nucmedbio.2007.06.015_bib6","first-page":"1001","article-title":"Protein deposits as the molecular basis of amyloidosis: Part I. Systemic amyloidoses","volume":"5","author":"Uversky","year":"1999","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.nucmedbio.2007.06.015_bib7","first-page":"1238","article-title":"Protein deposits as the molecular basis of amyloidosis: Part II. Localized amyloidosis and neurodegenerative disorders","volume":"5","author":"Uversky","year":"1999","journal-title":"Med Sci Monit"},{"issue":"1","key":"10.1016\/j.nucmedbio.2007.06.015_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506120500032196","article-title":"Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis","volume":"12","author":"Westermark","year":"2005","journal-title":"Amyloid"},{"issue":"10","key":"10.1016\/j.nucmedbio.2007.06.015_bib9","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1212\/01.wnl.0000256373.39415.b1","article-title":"Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis","volume":"68","author":"Forman","year":"2007","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.nucmedbio.2007.06.015_bib10","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1523\/JNEUROSCI.23-06-02086.2003","article-title":"The binding of 2-(4\u2032-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component","volume":"23","author":"Klunk","year":"2003","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.nucmedbio.2007.06.015_bib11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1212\/WNL.46.3.707","article-title":"Cerebral amyloid deposition and diffuse plaques in \u201cnormal\u201d aging: evidence for presymptomatic and very mild Alzheimer's disease","volume":"96","author":"Morris","year":"1996","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.nucmedbio.2007.06.015_bib12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X","article-title":"Tangles and plaques in nondemented aging and \u201cpreclinical\u201d Alzheimer's disease","volume":"45","author":"Price","year":"1999","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.nucmedbio.2007.06.015_bib13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/archneur.1995.00540280059019","article-title":"Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype","volume":"52","author":"Hyman","year":"1995","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.nucmedbio.2007.06.015_bib14","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","article-title":"[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease","volume":"67","author":"Mintun","year":"2006","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.nucmedbio.2007.06.015_bib15","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","article-title":"Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop","volume":"47","author":"McKeith","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.nucmedbio.2007.06.015_bib16","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.nucmedbio.2007.06.015_bib17","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","article-title":"Phases of A beta-deposition in the human brain and its relevance for the development of AD","volume":"58","author":"Thal","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nucmedbio.2007.06.015_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological staging of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2007.06.015_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cercor\/1.1.103","article-title":"The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease","volume":"1","author":"Arnold","year":"1991","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.nucmedbio.2007.06.015_bib20","first-page":"309","article-title":"Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease","volume":"135","author":"Joachim","year":"1989","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nucmedbio.2007.06.015_bib21","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/BF00687584","article-title":"Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by beta protein immunostain","volume":"77","author":"Yamaguchi","year":"1989","journal-title":"Acta Neuropathol"},{"issue":"12","key":"10.1016\/j.nucmedbio.2007.06.015_bib22","first-page":"1959","article-title":"Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis","volume":"46","author":"Lopresti","year":"2005","journal-title":"J Nucl Med"},{"issue":"20","key":"10.1016\/j.nucmedbio.2007.06.015_bib23","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","article-title":"Imaging beta-amyloid burden in aging and dementia","volume":"68","author":"Rowe","year":"2007","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.nucmedbio.2007.06.015_bib24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","article-title":"Amyloid deposition as the central event in the aetiology of Alzheimer's disease","volume":"12","author":"Hardy","year":"1991","journal-title":"Trends Pharmacol Sci"},{"issue":"5580","key":"10.1016\/j.nucmedbio.2007.06.015_bib25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.nucmedbio.2007.06.015_bib26","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.nucmedbio.2007.06.015_bib27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/156720506775697098","article-title":"Has the amyloid cascade hypothesis for Alzheimer's disease been proved?","volume":"3","author":"Hardy","year":"2006","journal-title":"Curr Alzheimer Res"},{"issue":"5","key":"10.1016\/j.nucmedbio.2007.06.015_bib28","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/1565","article-title":"Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau","volume":"1","author":"Hardy","year":"1998","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.nucmedbio.2007.06.015_bib29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev.neuro.21.1.479","article-title":"Mutant genes in familial Alzheimer's disease and transgenic models","volume":"21","author":"Price","year":"1998","journal-title":"Annu Rev Neurosci"},{"issue":"3","key":"10.1016\/j.nucmedbio.2007.06.015_bib30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1006\/nbdi.1996.0016","article-title":"The gene defects responsible for familial Alzheimer's disease","volume":"3","author":"Tanzi","year":"1996","journal-title":"Neurobiol Dis"},{"issue":"6 Pt B","key":"10.1016\/j.nucmedbio.2007.06.015_bib31","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1006\/nbdi.2000.0322","article-title":"FAD mutations in presenilin-1 or amyloid precursor protein decrease the efficacy of a gamma-secretase inhibitor: evidence for direct involvement of PS1 in the gamma-secretase cleavage complex","volume":"7","author":"Xia","year":"2000","journal-title":"Neurobiol Dis"},{"issue":"8","key":"10.1016\/j.nucmedbio.2007.06.015_bib32","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.neurobiolaging.2003.08.012","article-title":"Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease","volume":"24","author":"Oddo","year":"2003","journal-title":"Neurobiol Aging"},{"issue":"3","key":"10.1016\/j.nucmedbio.2007.06.015_bib33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","article-title":"Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction","volume":"39","author":"Oddo","year":"2003","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.nucmedbio.2007.06.015_bib34","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.neuron.2005.01.040","article-title":"Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice","volume":"45","author":"Billings","year":"2005","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.nucmedbio.2007.06.015_bib35","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.neuron.2004.07.003","article-title":"Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome","volume":"43","author":"Oddo","year":"2004","journal-title":"Neuron"},{"issue":"5534","key":"10.1016\/j.nucmedbio.2007.06.015_bib36","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1126\/science.1062097","article-title":"Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils","volume":"293","author":"Gotz","year":"2001","journal-title":"Science"},{"issue":"5534","key":"10.1016\/j.nucmedbio.2007.06.015_bib37","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1126\/science.1058189","article-title":"Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP","volume":"293","author":"Lewis","year":"2001","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.nucmedbio.2007.06.015_bib38","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.neurobiolaging.2004.02.010","article-title":"Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease","volume":"25","author":"Klein","year":"2004","journal-title":"Neurobiol Aging"},{"issue":"13","key":"10.1016\/j.nucmedbio.2007.06.015_bib39","doi-asserted-by":"crossref","first-page":"11612","DOI":"10.1074\/jbc.M210207200","article-title":"In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis","volume":"278","author":"Stine","year":"2003","journal-title":"J Biol Chem"},{"issue":"6740","key":"10.1016\/j.nucmedbio.2007.06.015_bib40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.nucmedbio.2007.06.015_bib41","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.bcp.2004.12.015","article-title":"Emerging prospects for the disease-modifying treatment of Alzheimer's disease","volume":"69","author":"Walker","year":"2005","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2007.06.015_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1750-3639.2004.tb00493.x","article-title":"Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease","volume":"14","author":"Ferrer","year":"2004","journal-title":"Brain Pathol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2007.06.015_bib43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/01.WNL.0000148590.39911.DF","article-title":"Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease","volume":"64","author":"Masliah","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nucmedbio.2007.06.015_bib44","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","article-title":"Neuropathology of human Alzheimer disease after immunization with amyloid-\u03b2 peptide: a case report","volume":"9","author":"Nicoll","year":"2003","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.nucmedbio.2007.06.015_bib45","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.tibs.2004.08.009","article-title":"Conformation-dependent antibodies target diseases of protein misfolding","volume":"29","author":"Glabe","year":"2004","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.nucmedbio.2007.06.015_bib46","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1742-2094-2-28","article-title":"Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease","volume":"2","author":"Zhou","year":"2005","journal-title":"J Neuroinflammation"},{"issue":"8","key":"10.1016\/j.nucmedbio.2007.06.015_bib47","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1074\/jbc.271.8.4077","article-title":"Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains","volume":"271","author":"Kuo","year":"1996","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.nucmedbio.2007.06.015_bib48","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","article-title":"Diffusible, nonfibrillar ligands derived from Abeta1\u201342 are potent central nervous system neurotoxins","volume":"95","author":"Lambert","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.nucmedbio.2007.06.015_bib49","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1042\/bst0300552","article-title":"Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition","volume":"30","author":"Walsh","year":"2002","journal-title":"Biochem Soc Trans"},{"issue":"5","key":"10.1016\/j.nucmedbio.2007.06.015_bib50","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nn842","article-title":"Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model","volume":"5","author":"Dodart","year":"2002","journal-title":"Nat Neurosci"},{"issue":"5","key":"10.1016\/j.nucmedbio.2007.06.015_bib51","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nm1234","article-title":"Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo","volume":"11","author":"Klyubin","year":"2005","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.nucmedbio.2007.06.015_bib52","doi-asserted-by":"crossref","first-page":"6331","DOI":"10.1523\/JNEUROSCI.22-15-06331.2002","article-title":"Reversible memory loss in a mouse transgenic model of Alzheimer's disease","volume":"22","author":"Kotilinek","year":"2002","journal-title":"J Neurosci"},{"issue":"5","key":"10.1016\/j.nucmedbio.2007.06.015_bib53","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1523\/JNEUROSCI.22-05-01858.2002","article-title":"The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease","volume":"22","author":"Westerman","year":"2002","journal-title":"J Neurosci"},{"issue":"18","key":"10.1016\/j.nucmedbio.2007.06.015_bib54","doi-asserted-by":"crossref","first-page":"10417","DOI":"10.1073\/pnas.1834302100","article-title":"Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss","volume":"100","author":"Gong","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"10.1016\/j.nucmedbio.2007.06.015_bib55","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","article-title":"Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease","volume":"98","author":"DeMattos","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 11","key":"10.1016\/j.nucmedbio.2007.06.015_bib56","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1093\/brain\/awl280","article-title":"Therapeutic approaches to Alzheimer's disease","volume":"129","author":"Klafki","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.nucmedbio.2007.06.015_bib57","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid \u03b2-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.nucmedbio.2007.06.015_bib58","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.nucmedbio.2007.06.015_bib59","first-page":"390","article-title":"Progress towards testing the amyloid hypothesis: inhibitors of APP processing","volume":"4","author":"Olson","year":"2001","journal-title":"Curr Opin Drug Discov Dev"},{"issue":"1","key":"10.1016\/j.nucmedbio.2007.06.015_bib60","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0014-5793(00)02076-7","article-title":"Regulation of APP cleavage by alpha-, beta- and gamma-secretases","volume":"483","author":"Nunan","year":"2000","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1016\/j.nucmedbio.2007.06.015_bib61","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1471-4159.2001.00012.x","article-title":"Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain","volume":"76","author":"Dovey","year":"2001","journal-title":"J Neurochem"},{"issue":"51","key":"10.1016\/j.nucmedbio.2007.06.015_bib62","doi-asserted-by":"crossref","first-page":"41987","DOI":"10.1074\/jbc.M501368200","article-title":"Gamma-secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site","volume":"280","author":"Fraering","year":"2005","journal-title":"J Biol Chem"},{"issue":"26","key":"10.1016\/j.nucmedbio.2007.06.015_bib63","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1021\/bi060799c","article-title":"The gamma-secretase complex: membrane-embedded proteolytic ensemble","volume":"45","author":"Wolfe","year":"2006","journal-title":"Biochemistry"},{"issue":"12","key":"10.1016\/j.nucmedbio.2007.06.015_bib64","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/hmg\/10.12.1317","article-title":"BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics","volume":"10","author":"Roberds","year":"2001","journal-title":"Hum Mol Genet"},{"issue":"7","key":"10.1016\/j.nucmedbio.2007.06.015_bib65","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1474-4422(02)00188-6","article-title":"Secretases as targets for the treatment of Alzheimer's disease: the prospects","volume":"1","author":"Dewachter","year":"2002","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.nucmedbio.2007.06.015_bib66","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bbapap.2003.11.035","article-title":"Crystallization of glycosylated human BACE protease domain expressed in Trichoplusia ni","volume":"1698","author":"Wang","year":"2004","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.nucmedbio.2007.06.015_bib67","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrd2314","article-title":"Therapies for Alzheimer's disease","volume":"6","author":"Melnikova","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.nucmedbio.2007.06.015_bib68","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/01.wnf.0000167360.27670.29","article-title":"Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers","volume":"28","author":"Siemers","year":"2005","journal-title":"Clin Neuropharmacol"},{"issue":"6860","key":"10.1016\/j.nucmedbio.2007.06.015_bib69","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35102591","article-title":"A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity","volume":"414","author":"Weggen","year":"2001","journal-title":"Nature"},{"issue":"34","key":"10.1016\/j.nucmedbio.2007.06.015_bib70","doi-asserted-by":"crossref","first-page":"31831","DOI":"10.1074\/jbc.M303592200","article-title":"Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity","volume":"278","author":"Weggen","year":"2003","journal-title":"J Biol Chem"},{"issue":"21","key":"10.1016\/j.nucmedbio.2007.06.015_bib71","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial","volume":"289","author":"Aisen","year":"2003","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.nucmedbio.2007.06.015_bib72","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1006\/nbdi.2001.0422","article-title":"A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease","volume":"8","author":"Refolo","year":"2001","journal-title":"Neurobiol Dis"},{"issue":"4","key":"10.1016\/j.nucmedbio.2007.06.015_bib73","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1073\/pnas.0436286100","article-title":"Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology","volume":"100","author":"Bard","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"10.1016\/j.nucmedbio.2007.06.015_bib74","doi-asserted-by":"crossref","first-page":"7873","DOI":"10.1523\/JNEUROSCI.22-18-07873.2002","article-title":"Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy","volume":"22","author":"Bacskai","year":"2002","journal-title":"J Neurosci"},{"issue":"8","key":"10.1016\/j.nucmedbio.2007.06.015_bib75","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1073\/pnas.94.8.4109","article-title":"Disaggregation of Alzheimer beta-amyloid by site-directed mAb","volume":"94","author":"Solomon","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"10.1016\/j.nucmedbio.2007.06.015_bib76","doi-asserted-by":"crossref","first-page":"8532","DOI":"10.1523\/JNEUROSCI.23-24-08532.2003","article-title":"Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma\u2212\/\u2212 knock-out mice","volume":"23","author":"Das","year":"2003","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.nucmedbio.2007.06.015_bib77","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0969-9961(03)00044-5","article-title":"Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice","volume":"14","author":"Lemere","year":"2003","journal-title":"Neurobiol Dis"},{"issue":"7","key":"10.1016\/j.nucmedbio.2007.06.015_bib78","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1074\/jbc.M404751200","article-title":"Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo","volume":"280","author":"Yang","year":"2005","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.nucmedbio.2007.06.015_bib79","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0959-440X(03)00100-3","article-title":"Design strategies for anti-amyloid agents","volume":"13","author":"Mason","year":"2003","journal-title":"Curr Opin Struct Biol"},{"issue":"2","key":"10.1016\/j.nucmedbio.2007.06.015_bib80","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm0295-143","article-title":"Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease","volume":"1","author":"Kisilevsky","year":"1995","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.nucmedbio.2007.06.015_bib81","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0197-4580(02)00120-3","article-title":"Metal complexing agents as therapies for Alzheimer's disease","volume":"23","author":"Bush","year":"2002","journal-title":"Neurobiol Aging"},{"issue":"4","key":"10.1016\/j.nucmedbio.2007.06.015_bib82","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0166-2236(03)00067-5","article-title":"The metallobiology of Alzheimer's disease","volume":"26","author":"Bush","year":"2003","journal-title":"Trends Neurosci"},{"issue":"3","key":"10.1016\/j.nucmedbio.2007.06.015_bib83","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0896-6273(01)00317-8","article-title":"Treatment with a copper\u2013zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice","volume":"30","author":"Cherny","year":"2001","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.nucmedbio.2007.06.015_bib84","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.nucmedbio.2007.06.015_bib85","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.coi.2004.08.002","article-title":"Toward modeling hemorrhagic and encephalitic complications of Alzheimer amyloid-beta vaccination in nonhuman primates","volume":"16","author":"Gandy","year":"2004","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.nucmedbio.2007.06.015_bib86","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0896-6273(03)00294-0","article-title":"Antibodies against \u03b2-amyloid slow cognitive decline in Alzheimer's disease","volume":"38","author":"Hock","year":"2003","journal-title":"Neuron"},{"issue":"9","key":"10.1016\/j.nucmedbio.2007.06.015_bib87","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1212\/01.WNL.0000159743.08996.99","article-title":"Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease","volume":"64","author":"Fox","year":"2005","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.nucmedbio.2007.06.015_bib88","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1016\/j.febslet.2005.03.070","article-title":"Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis","volume":"579","author":"Lee","year":"2005","journal-title":"FEBS Lett"},{"issue":"9","key":"10.1016\/j.nucmedbio.2007.06.015_bib89","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1177\/002215540004800906","article-title":"X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology","volume":"48","author":"Styren","year":"2000","journal-title":"J Histochem Cytochem"},{"issue":"2","key":"10.1016\/j.nucmedbio.2007.06.015_bib90","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/archneur.62.2.196","article-title":"Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies","volume":"62","author":"Mathis","year":"2005","journal-title":"Arch Neurol"},{"issue":"25","key":"10.1016\/j.nucmedbio.2007.06.015_bib91","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMoa054625","article-title":"PET of brain amyloid and tau in mild cognitive impairment","volume":"355","author":"Small","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.nucmedbio.2007.06.015_bib92","first-page":"584","article-title":"In-vivo imaging of Alzheimer disease {beta}-amyloid with [11C]SB-13 PET","volume":"12","author":"Verhoeff","year":"2004","journal-title":"Am J Geriatr Psychiatry"},{"issue":"9518","key":"10.1016\/j.nucmedbio.2007.06.015_bib93","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/S0140-6736(06)68542-5","article-title":"Mild cognitive impairment","volume":"367","author":"Gauthier","year":"2006","journal-title":"Lancet"},{"issue":"Pt 11","key":"10.1016\/j.nucmedbio.2007.06.015_bib94","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1093\/brain\/awl281","article-title":"Two-year follow-up of amyloid deposition in patients with Alzheimer's disease","volume":"129","author":"Klunk","year":"2006","journal-title":"Brain"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805107001771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805107001771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T21:07:36Z","timestamp":1556831256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805107001771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":94,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0969805107001771"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2007.06.015","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}